Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical trial NCT07727668 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07727668
- Sponsor
- Shambavi Richard
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2027-07-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.